EMTome

EMTome enables pan-cancer analysis of epithelial-mesenchymal transition (EMT) genes and signatures to investigate molecular drivers of metastatic progression and prognostic markers such as FGFR1, β3 integrin, and FAK.

Key Features:

• Pan-Cancer Analysis: Performs comparative analysis of EMT-related genes and pathways across multiple cancer types.
• EMT Signature Identification: Detects and catalogs molecular signatures associated with epithelial-mesenchymal transition.
• Predictive Molecular Signatures: Identifies prognostic markers including FGFR1, β3 integrin, and FAK correlated with patient survival in subtypes such as basal-like breast cancer.
• Mechanistic Data Integration: Integrates mechanistic findings on β3 integrin, FGFR1, FGF2 signaling, and FAK activity into analyses.
• Clinical Correlation Analyses: Supports correlation of molecular signatures with clinical outcomes and prognostic assessment.
• Preclinical Inhibitor Evaluation: Incorporates data relevant to evaluation of inhibitors such as FIIN-4 in preclinical contexts.

Scientific Applications:

• Metastatic Research: Investigates how EMT-associated genes contribute to acquisition of metastatic capabilities.
• Therapeutic Targeting: Supports identification of EMT program components, such as FGFR1 and β3 integrin, as potential therapeutic targets.
• Drug Development: Facilitates evaluation of candidate therapeutics, exemplified by FIIN-4, that disrupt EMT-related signaling pathways.
• Mechanistic Studies: Enables exploration of interactions among β3 integrin, FGFR1, E-cadherin, and downstream signaling in cancer cell behavior.
• Clinical Correlation: Allows association of EMT signatures with clinical outcomes to inform prognostic marker development.
• Preclinical Testing: Assists assessment of inhibitor efficacy and mechanistic impact in preclinical models.

Methodology:

Leverages and integrates published study data, incorporating mechanistic findings that β3 integrin alters FGFR1 subcellular localization to enhance FGF2 signaling and 3D outgrowth, and integrates findings on FAK enzymatic activity.